Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd. more
Time Frame | NKGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 18.91% | 2.3% | 1.73% |
1-Month Return | 6.34% | -1.77% | 3.44% |
3-Month Return | -50.33% | -6.07% | 7.02% |
6-Month Return | -75.19% | 2.45% | 13.38% |
1-Year Return | -87.08% | 12.17% | 32.25% |
3-Year Return | -96.16% | 10.46% | 29.27% |
5-Year Return | -96.16% | 46.4% | 90.61% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 426.00K | 77.00K | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":18.08,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | 30.00K | 18.00K | 1.20M | [{"date":"2021-12-31","value":2.49,"profit":true},{"date":"2022-12-31","value":1.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | 396.00K | 59.00K | (1.20M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":14.9,"profit":true},{"date":"2023-12-31","value":-303.79,"profit":false}] | ||
Gross Margin | 92.96% | 76.62% | - | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.43,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | 22.26M | 24.41M | 28.54M | [{"date":"2021-12-31","value":77.98,"profit":true},{"date":"2022-12-31","value":85.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (21.86M) | (24.35M) | (29.75M) | [{"date":"2021-12-31","value":-2186100000,"profit":false},{"date":"2022-12-31","value":-2434600000,"profit":false},{"date":"2023-12-31","value":-2974600000,"profit":false}] | ||
Total Non-Operating Income/Expense | (2.71M) | (4.71M) | (53.95M) | [{"date":"2021-12-31","value":-271400000,"profit":false},{"date":"2022-12-31","value":-470700000,"profit":false},{"date":"2023-12-31","value":-5394600000,"profit":false}] | ||
Pre-Tax Income | (23.26M) | (26.75M) | (82.95M) | [{"date":"2021-12-31","value":-2326000000,"profit":false},{"date":"2022-12-31","value":-2674700000,"profit":false},{"date":"2023-12-31","value":-8294700000,"profit":false}] | ||
Income Taxes | 5.00K | 7.00K | 7.00K | [{"date":"2021-12-31","value":71.43,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Income After Taxes | (23.27M) | (26.75M) | (82.95M) | [{"date":"2021-12-31","value":-2326500000,"profit":false},{"date":"2022-12-31","value":-2675400000,"profit":false},{"date":"2023-12-31","value":-8295400000,"profit":false}] | ||
Income From Continuous Operations | (23.27M) | (26.75M) | (82.95M) | [{"date":"2021-12-31","value":-2326500000,"profit":false},{"date":"2022-12-31","value":-2675400000,"profit":false},{"date":"2023-12-31","value":-8295400000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (23.27M) | (26.75M) | (82.95M) | [{"date":"2021-12-31","value":-2326500000,"profit":false},{"date":"2022-12-31","value":-2675400000,"profit":false},{"date":"2023-12-31","value":-8295400000,"profit":false}] | ||
EPS (Diluted) | (0.05) | 0.21 | (4.10) | [{"date":"2021-12-31","value":-23.81,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1953.67,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
NKGN | |
---|---|
Cash Ratio | 0.00 |
Current Ratio | 0.02 |
Quick Ratio | 0.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NKGN | |
---|---|
ROA (LTM) | -106.85% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NKGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 5.46 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -4.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NKGN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1215.21 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 964.78 |
EV/Ebitda | NM |
NKGen Biotech, Inc. Common Stock (NKGN) share price today is $0.3722
Yes, Indians can buy shares of NKGen Biotech, Inc. Common Stock (NKGN) on Vested. To buy NKGen Biotech, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NKGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NKGen Biotech, Inc. Common Stock (NKGN) via the Vested app. You can start investing in NKGen Biotech, Inc. Common Stock (NKGN) with a minimum investment of $1.
You can invest in shares of NKGen Biotech, Inc. Common Stock (NKGN) via Vested in three simple steps:
The 52-week high price of NKGen Biotech, Inc. Common Stock (NKGN) is $4. The 52-week low price of NKGen Biotech, Inc. Common Stock (NKGN) is $0.2.
The price-to-earnings (P/E) ratio of NKGen Biotech, Inc. Common Stock (NKGN) is
The price-to-book (P/B) ratio of NKGen Biotech, Inc. Common Stock (NKGN) is 0.00
The dividend yield of NKGen Biotech, Inc. Common Stock (NKGN) is 0.00%
The market capitalization of NKGen Biotech, Inc. Common Stock (NKGN) is $12.85M
The stock symbol (or ticker) of NKGen Biotech, Inc. Common Stock is NKGN